Literature DB >> 9817853

Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group.

P Sandven1, L Bevanger, A Digranes, P Gaustad, H H Haukland, M Steinbakk.   

Abstract

Since 1991 information on yeast isolates from blood cultures has been recorded prospectively from all microbiological laboratories (5 university and 16 county or local hospital laboratories) in Norway (population, 4.3 million). From 1991 to 1996 a total of 571 episodes of fungemia in 552 patients occurred (1991, 109 episodes; 1992, 81 episodes; 1993, 93 episodes; 1994, 89 episodes; 1995, 98 episodes; and 1996, 101 episodes). The fungemia rates per 10,000 patient days were 0.29 in 1991 and 0.27 in 1996. The average rates for the years 1991 to 1996 were 0.37 for the university laboratories and 0.20 for the other laboratories. These rates are low compared to the rate (0. 76) in five Dutch university hospitals in 1995 and the rate (2.0) in Iowa in 1991. The four most frequently isolated species were Candida albicans (66%), Candida glabrata (12.5%), Candida parapsilosis (7.6%), and Candida tropicalis (6.4%). The incidences of both C. albicans (range, 63 to 73%) and C. glabrata (range, 8.4 to 15.7%) varied somewhat throughout this period, but no significant increase or decrease was noted. MICs of amphotericin B, flucytosine, and fluconazole were determined for 89% of the isolates. All were susceptible to amphotericin B, and only 29 (5.6%) strains had decreased susceptibility to flucytosine. All C. albicans isolates were susceptible to fluconazole. The percentage of yeast isolates with decreased susceptibility to fluconazole (MICs, >/=16 microgram/ml) did increase, from 9.6% in 1991 and 1992 to 12.2% in 1994, 16.1% in 1995, and 18.6% in 1996. This was largely due to increases in the percentages of resistant C. glabrata and Candida krusei strains in the last 2 years. Compared to the incidence in other countries, it is remarkable that Norway has such a low and constant incidence of fungemia. A possible reason for this difference might be a restricted antibiotic use policy in Norway.

Entities:  

Mesh:

Year:  1998        PMID: 9817853      PMCID: PMC105220     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Antifungal susceptibility pattern of non-albicans Candida species & distribution of species isolated from Candidaemia cases over a 5 year period.

Authors:  A Chakrabarti; A Ghosh; R Batra; A Kaushal; P Roy; H Singh
Journal:  Indian J Med Res       Date:  1996-08       Impact factor: 2.375

2.  Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals.

Authors:  A Voss; J A Kluytmans; J G Koeleman; L Spanjaard; C M Vandenbroucke-Grauls; H A Verbrugh; M C Vos; A Y Weersink; J A Hoogkamp-Korstanje; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

Review 3.  Antifungal susceptibility testing: technical advances and potential clinical applications.

Authors:  M A Pfaller; J H Rex; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

4.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Laboratory identification and sensitivity testing of yeast isolates.

Authors:  P Sandven
Journal:  Acta Odontol Scand       Date:  1990-02       Impact factor: 2.331

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

7.  Fungemia: An increasing problem in a Danish university hospital 1989 to 1994.

Authors:  Brita Bruun; Henrik Westh; Jørgen Stenderup
Journal:  Clin Microbiol Infect       Date:  1995-02       Impact factor: 8.067

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

9.  Nosocomial candidemia in a university hospital in Taiwan.

Authors:  C C Hung; Y C Chen; S C Chang; K T Luh; W C Hsieh
Journal:  J Formos Med Assoc       Date:  1996-01       Impact factor: 3.282

10.  A study of 666 strains of Candida albicans: correlation between serotype and susceptibility to 5-fluorocytosine.

Authors:  P Auger; C Dumas; J Joly
Journal:  J Infect Dis       Date:  1979-05       Impact factor: 5.226

View more
  23 in total

1.  One-year prevalence of Candida dublinienis in a Dutch university hospital.

Authors:  J F Meis; F M Lunel; P E Verweij; A Voss
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

3.  Candidemia in Norway (1991 to 2003): results from a nationwide study.

Authors:  Per Sandven; Lars Bevanger; Asbjørn Digranes; Hanne H Haukland; Turid Mannsåker; Peter Gaustad
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Candida spp. colonization significance in critically ill medical patients: a prospective study.

Authors:  Pierre Emmanuel Charles; Frédéric Dalle; Hervé Aube; Jean Marc Doise; Jean Pierre Quenot; Ludwig Serge Aho; Pascal Chavanet; Bernard Blettery
Journal:  Intensive Care Med       Date:  2005-02-12       Impact factor: 17.440

5.  Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.

Authors:  Maiken Cavling Arendrup; Kurt Fuursted; Bente Gahrn-Hansen; Irene Møller Jensen; Jenny Dahl Knudsen; Bettina Lundgren; Henrik C Schønheyder; Michael Tvede
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain.

Authors:  J Pemán; E Cantón; M Gobernado
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

7.  Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

Authors:  Benito Almirante; Dolors Rodríguez; Benjamin J Park; Manuel Cuenca-Estrella; Ana M Planes; Manuel Almela; Jose Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Pere Saballs; Scott K Fridkin; Juliette Morgan; Juan L Rodriguez-Tudela; David W Warnock; Albert Pahissa
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

8.  Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.

Authors:  Guy St-Germain; Michel Laverdière; René Pelletier; Pierre René; Anne-Marie Bourgault; Claude Lemieux; Michael Libman
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

9.  New approach for diagnosis of candidemia based on detection of a 65-kilodalton antigen.

Authors:  Rodrigo Berzaghi; Arnaldo Lopes Colombo; Antonia Maria de Oliveira Machado; Zoilo Pires de Camargo
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

10.  Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland.

Authors:  Lena Rós Asmundsdóttir; Helga Erlendsdóttir; Magnús Gottfredsson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.